Immune-Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex). [PDF]
Iessa K +5 more
europepmc +1 more source
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. [PDF]
Eefsen RL +14 more
europepmc +1 more source
Bladder metastasis from cutaneous melanoma during adjuvant immunotherapy: A case report and literature review. [PDF]
Marafioti M +8 more
europepmc +1 more source
Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database. [PDF]
Yang Y +6 more
europepmc +1 more source
Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. <i>J. Clin. Med.</i> 2021, <i>10</i>, 5325. [PDF]
Iinuma K +15 more
europepmc +1 more source
Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab. [PDF]
Numakura K, Abe N.
europepmc +1 more source
Comparison of Long-Term Survival Between Nivolumab Plus Ipilimumab and Nivolumab Plus Ipilimumab With Chemotherapy in Advanced NSCLC: A Multicenter Retrospective Cohort Study. [PDF]
Komuta K +18 more
europepmc +1 more source
First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. [PDF]
Shah A +7 more
europepmc +1 more source

